Foundation Medicine to Share 14 Abstracts at the 2022 European Society for Medical Oncology (ESMO) Congress Demonstrating the Power of Genomic…

Posted: September 8, 2022 at 2:17 am

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, today announced that the company and its collaborators will present 14 abstracts at the 2022 European Society for Medical Oncology Congress being held virtually and in person in Paris from September 9-13, 2022.

Highlights from the presentations include:

This data demonstrates the power of our tissue- and liquid-based comprehensive genomic profiling tests for enabling critical research on complex genomic signatures and emerging biomarkers, said Priti Hegde, PhD, Chief Scientific Officer at Foundation Medicine. Were proud to be working across the cancer research community to deepen our collective understanding of cancer biology and ultimately support better care for patients in the future.

The following is a list of abstracts that will be presented at the meeting. To access all abstracts being presented at ESMO, please visit: https://oncologypro.esmo.org/meeting-resources/esmo-congress

Follow Foundation Medicine on Twitter and LinkedIn for more updates from #ESMO22 and visit us in person at booth #306.

Abstract #

Title

Product*

Collaborators

Proffered Paper Session

Sunday, September 11, 2022,

4:40 - 4:50 PM CET

#1696O

Genomic profiling and molecular targeting of lung cancer brain metastases

FoundationOne CDx

Montefiore Einstein Cancer Center

Mini Oral Sessions

Saturday, September 10, 2022,

11:15 - 11:20 AM CET

#660MO

Molecular targets in salivary gland cancers: A comprehensive genomic analysis of 1,666 cases

FoundationOne CDx

Upstate Medical University

Monday, September 12, 2022,

3:35 - 3:40 PM CET

#1487MO

A pan-sarcoma investigation of genetic alterations associated with high telomeric content

FoundationOne Heme

Omico (Australian genomic Cancer Medicine), Garvan Institute of Medical Research; St Vincents Clinical School, University of New South Wales, Australia

Posters

Saturday, September 10, 2022

#97P

Pan-cancer landscape of clonal tumor mutational burden (cTMB)

FoundationOne CDx

Massachusetts General Cancer Center, MA, USA; Harvard Medical School, MA, USA; Georgia Institute of Technology, GA, USA; Massachusetts General Hospital, MA, US

Saturday, September 10, 2022

#100P

Co-mutational landscape of key fibroblast growth factor receptor (FGFR) alterations in intra-hepatic cholangiocarcinoma (iCCA), bladder cancer (BC) and glioma

FoundationOne CDx

Ospedale San Raffaele,

Vita-Salute San Raffaele University, Milan, Italy; Tyra Biosciences, Carlsbad, CA, USA; F. Hoffmann-La Roche Ltd, Basel, Switzerland; Jefferson Health, Philadelphia, PA, USA; Ohio State University, Columbus, OH, USA; Repare Therapeutics, Cambridge, MA, USA; Hannover Medical School, Hannover, Germany

Sunday, September 11, 2022

#1373P

SPOP mutations (mtSPOP) are a treatment-selection biomarker in patients (pts) with de novo metastatic castration-sensitive prostate cancer (dn-mCSPC).

Clinico-Genomic Database (CGDB)

Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah; University of Minnesota Masonic Cancer Center, Minneapolis, MN

Sunday, September 11, 2022

#1393P

Comparison of genomic alterations (GA) landscape in SPOP mutated (SPOPmut) and SPOP wild type (SPOPwt) clinically advanced prostate cancer (CAPC)

FoundationOne CDx

Ospedale San Raffaele,

Vita-Salute San Raffaele University, Milan, Italy/Moffitt Cancer Center/SUNY Upstate Medical University

Sunday, September 11, 2022

#1368P

TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage response alterations (DDRm)Exploration of tumor genetics associated with prolonged benefit

FoundationOne CDx

The Institute of Cancer Research and The Royal Marsden Hospital, London, UK; various other institutions; Pfizer

Sunday, September 11, 2022

#1521P

Comprehensive genomic profiling (CGP) of epithelioid hemangioendothelioma (EHE) and liver angiosarcomas (LAS)

FoundationOne CDx

Medical College of Wisconsin

Excerpt from:
Foundation Medicine to Share 14 Abstracts at the 2022 European Society for Medical Oncology (ESMO) Congress Demonstrating the Power of Genomic...

Related Post